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OBJECTIVES: While some complementary and alternative medicine (CAM) modali-
ties are known to be effective in treating and/or managing anxiety and depres-
sion, relatively little is known about the patterns of CAM use among U.S. adults 
with moderate mental distress (MMD). We (1) examined whether the prevalence 
rates of CAM use varies by race/ethnicity in U.S. adults with MMD, and (2) assessed 
which socio-demographic and health-related factors are associated with CAM use 
among these racially/ethnically diverse groups. METHODS: We used data collected 
from 2012 National Health Interview Survey (NHIS), which represents non-insti-
tutionalized U.S. adults with MMD (n= 6,016 unweighted). Using a cross-sectional 
design with survey data analysis techniques, we conducted descriptive analyses for 
prevalence rates of CAM use and multivariate logistic regression analyses to predict 
CAM use. RESULTS: Among adults with MMD, the overall prevalence of past year 
CAM use was significantly different across racial/ethnic groups (P< 0.0001), with 
Asians (44.7%) and others (46.8%) having the highest prevalence rates. Blacks and 
Hispanics had prevalence rates of 24.3% and 30.7%, respectively, which were lower 
than non-Hispanic Whites (44.3%). When controlling for other relevant factors, being 
younger in age (18-64), being female, living in the West, having higher educational 
attainment, being employed, having more than four ambulatory care visits and 
functional limitations were significantly associated with higher odds of CAM use 
(P< 0.05). CONCLUSIONS: Racial/ethnic differences exist in CAM use among U.S. 
adults with MMD. We also observed factors associated with higher odds of such CAM 
use, such as age, gender, geographic location, employment status, frequent ambu-
latory care visits, and functional limitations. To improve patient-centered mental 
health care, which may include integration of CAM use, mental health professionals 
and researchers should acknowledge that racial/ethnic differences exist in CAM use. 
Further studies are needed to explore why such patterns exist, and consequently, 
affect racial/ethnic minorities’ mental health.
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OBJECTIVES: The objective of this study was to examine the impact of obesity 
on one’s physical and mental health, healthcare costs and satisfaction with their 
healthcare. We hypothesized that obese respondents would report worse physical 
and mental health, higher medical costs and poorer satisfaction with their health-
care than patients without a diagnosis of obesity. METHODS: A representative 
(U.S.) sample of 5,000 adults completed an online survey regarding their health 
and healthcare. We compared respondents who were previously diagnosed with 
obesity to those who were not. We conducted bivariate analyses and multivariate 
logistic regression to assess the relationship between obesity and the outcomes of 
interest. RESULTS: 12% (n= 609) of respondents reported having been diagnosed 
with obesity. In bivariate analysis obese respondents reported worse overall physical 
health (p< .00001) and mental health (p < .0001). Additionally, respondents with a 
diagnosis of obesity were more likely to screen positive (20.8% vs 12%) on the PHQ-2 
depression screener (p < . 05). While out of pocket costs were significantly higher 
in obese respondents (p < .05), non-obese respondents tended to report paying 
more for their health insurance premiums (p< .05). Obesity was also associated 
with having more comorbid conditions (2.7 vs 1.9 respectively; p < .0001). Levels of 
satisfaction with the health system, their healthcare plan and healthcare provider 
between the groups varied. Multivariate analyses controlling for potential confound-
ing factors, including comorbidities, as expected impacted these findings and will 
be presented. CONCLUSIONS: Obesity is a public health epidemic and contributes 
to poor health outcomes. As the U.S. healthcare delivery system moves toward 
population based health care approaches, more research among obese individuals 
is needed to better understand the association between obesity and poor outcomes 
but also the relationship with other independent predictors that can be modified 
or addressed to enhance the health of our nation.
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OBJECTIVES: Underuse of clozapine, an evidence-based practice, and overuse of 
non-clozapine antipsychotic polypharmacy (hereafter, antipsychotic polyphar-
macy), an unsupported practice to treat patients with schizophrenia may result in 
undesirable consequences. This study evaluated provider-level prevalence of clozap-
ine and antipsychotic polypharmacy prescribing and associated factors. METHODS: 
Using 2010-2012 data from Pennsylvania’s Medicaid we identified all providers who 
regularly prescribed antipsychotics to non-elderly adult patients with schizophrenia 
(defined as ≥ 10 patients/year). We characterized providers’ patients and payers 
(managed care vs. fee-for-service) using Medicaid data, and providers’ demographics 
using CMS’s NPI file. We measured provider-level share of patients with clozapine 
use and antipsychotic polypharmacy use per year. Antipsychotic polypharmacy was 
defined as more than 90 days’ concurrent use of ≥ 2 non-clozapine antipsychotics, 
with 32-day gap allowance. We used generalized estimating equations with a bino-
mial distribution and a logit link to examine clozapine and antipsychotic polyphar-
macy practices and associated patient- and provider-level factors. RESULTS: The 
analytic cohort included 632-650 prescribers per year. Provider-level clozapine and 
antipsychotic polypharmacy practices were relatively stable over time. In 2012, pro-
vider-level mean shares of patients with clozapine and antipsychotic polypharmacy 
use were 6.9% (range: 0%-88.9%) and 7.0% (range: 0%-45.2%), respectively. A sizable 
proportion of providers prescribed antipsychotic polypharmacy but not clozapine 
(e.g., 15.5% in 2012). High volume prescribers were much more likely to prescribe 
clozapine (OR = 1.43, p< 0.01) and antipsychotic polypharmacy (OR = 2.65, p< 0.01) 
matched JC and non-JC patients to evaluate effectiveness of the program is on-
going. RESULTS: A total of 102 JC patients were included (15 continuous users 
and 87 new users). The mean age was 41 years (SD=13), 63% were males, 64% 
were covered by Medicaid, or Medicare, or dually covered, 63% lived with family/
friends and 29%, 30% and 25% had comorbidity conditions of depression, anxiety 
and bipolar disorder, respectively.  In the pre-index period, 22% of JC patients had 
any use of inpatient hospitalization, emergency room (ER) or crisis stabilization 
unit (20%, 1% and 5%, respectively) and 77% had outpatient visits.  Pre-index oral 
atypical antipsychotics (73%) and antidepressants (59%) were commonly used.  In 
the post- index period, 18% of patients had any use of inpatient hospitalization, ER 
or crisis stabilization unit (15%, 2% and 3%, respectively) and 84% had outpatient 
visits. Post-index oral atypical antipsychotics and antidepressant use was 59% 
and 57%, respectively. CONCLUSIONS: Preliminary evidence shows numerically 
lower inpatient, ER and crisis unit utilization from pre- to post-index period among 
schizophrenia JC enrollees.
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OBJECTIVES: To explore medication use patterns, health-care resource utili-
zation and economic burden among patients with schizophrenia in Beijing, 
China. METHODS: A retrospective analysis was performed using the Beijing Urban 
Employee Basic Medical Insurance Database from January 1, 2011 to December 31, 
2013. Patients diagnosed with schizophrenia were identified using the International 
Classification of Disease 10th diagnosis codes F20, and the first diagnosis date in 
2012 was designated as the index date. Patients were required to be at least 18 years 
old, without any cancer and with 12-months continuous enrollment after the index 
date. Descriptive statistics were used to describe patient profiles, medication usage, 
health-care resource utilization and annual direct medical costs during the 1-year 
follow-up period. RESULTS: A total of 17,609 patients were included with mean 
(±SD) age of 52 (±15) years, 54% females and 94% with the baseline medical co-
morbidities. During the study follow-up, 75% received antipsychotic monotherapy 
and 84% were treated with atypical antipsychotics. The proportion of patients with 
schizophrenia-related hospitalization was 9.6%, with 1.2 (±0.5) hospitalizations per 
patient-year, 118 (±98) days of total length of hospitalization stay per patient-year, 
and a 21% re-admission rate. Those with any schizophrenia-related outpatient visit 
had 5.7 (±4.4) outpatient visits per patient-year, with 82% having at least 2 outpatient 
visits. The all-cause annual direct medical costs per patient were $2,668 (±3,511), 
while schizophrenia-related annual costs were $950 (±2,150). The costs per schizo-
phrenia-related hospitalization were $4,050 (±3,592), with 10% of costs attributable 
to antipsychotics and 81% to non-medication medical costs. CONCLUSIONS: In 
Beijing, patients diagnosed with schizophrenia had a low rate of schizophrenia-
related hospitalization, and a high rate of medical co-morbidities. Most patients 
received antipsychotic monotherapy and atypical antipsychotics. The economic 
burden associated with schizophrenia was considerable.
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OBJECTIVES: To investigate Internet addiction (IA) among the students of three 
major universities: Astana Medical University (Kazakhstan), Ukrainian Medical 
Stomatological Academy (Ukraine) and Tashkent Institute of Railway Transport 
Engineers (Uzbekistan). METHODS: Our study was based on a questionnaire, which 
included two sections: demographic part and a traditional K.Yang’s questionnaire. 
Problematic Internet Use (PIU) indices were calculated according to 4 scales: social 
comfort, loneliness, distraction, and impulsiveness. We used Student’s t-test, 
Spearmen’s rank correlation coefficient and Cronbach alpha coefficient. RESULTS: 
The majority of male and female students reported about using Internet five or more 
times a week. It was detected a statistically significant difference between men and 
women according to the latter type of activity, where females were more likely to use 
the Internet for entertainment than males (p< 0.05). Data showed statistically signifi-
cant differences among men. The same comparison among women did not find any 
significant differences. IA disorder can lead to «Dry eye» syndrome, carpal tunnel 
syndrome (6,8%), neuroses, backaches and neckaches among young people. One of 
four respondents noted that they had an experienced pain, numbness in hands and 
wrists. Almost half of the students complain that they are concerned about their 
eyesight. The high value of the Spearman rank correlation coefficient (ranging from 
0.91 to 0.99) testifies about the inverse association between the number of answers 
and their rank. CONCLUSIONS: When all results were compared, statistically sig-
nificant differences of the comparative characterization of PIU among students by 
gender did not found (p> 0.05). The null hypothesis, which has proved the lack of 
differences in indicators of addictive behavior among students, is not confirmed. 
We found higher PIU indices among Kazakhstani students in the category of Social 
Comfort, in comparison with the students from Uzbekistan, having high PIU indices 
in the category of Diminished Impulse Control.
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ing multiple academic programs. Using ASRS-v1.1 symptom cut-off threshold, a 
prevalence rate of ADHD symptoms ranging from 21.2% to 66.2% (indicating likeli-
hood and immense likelihood of ADHD respectively) was observed for the general 
student sample. Only 3.4% of the participants had been previously diagnosed with 
ADHD. The prevalence of self-reported ADHD symptoms was higher in the age group 
of 18-23 years (81.3%) and was greater in females (53.1%). A majority of students 
had the inattentive type of symptomatology (72.72%). With regard to different 
disciplines, prevalence rates ranged from 49% (pharmacy school) to 5.9% (school 
of education). More undergraduate students reported AADHD symptoms (70.9%) 
compared to graduate students (28.4%). Students in healthcare discipline reported 
greater ADHD symptomatology (54.6%) compared to students in non-healthcare 
fields. CONCLUSIONS: Symptoms of AADHD appear to be more prevalent in stu-
dent populations than documented evidence would suggest. Among many that are 
affected, most are either unaware of the condition or undiagnosed. These findings 
have implications for students’ overall health and academic performance.
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OBJECTIVES: Given considerable variability in treatment response and medication 
side effects across individual patients using antipsychotics, customizing treatment 
to the needs of each individual is key to improving patient outcomes. This study 
examined the degree to which psychiatrists were diversified vs. concentrated in 
their choice of antipsychotic medication and identified factors associated with 
their prescribing. METHODS: Using 2011 data from Pennsylvania’s Medicaid we 
identified psychiatrists who regularly prescribed antipsychotics (defined as ≥ 10 
nonelderly patients). Using prescriber ID we linked claims data, from which we 
obtained information on patient characteristics and psychiatrist prescribing behav-
ior, to demographic information on psychiatrists from the AMA Masterfile, and to 
information on organizational affiliations from IMS Health’s HCOS TM database. 
We used three measures of antipsychotic prescribing concentration: Herfindahl 
index (HHI), share of most preferred ingredient, and number of ingredients. We 
used multiple membership linear mixed models to evaluate the degree of con-
centration for antipsychotic prescribing. Predictors included patient-, physician-, 
and organization-level factors. RESULTS: The analytic cohort included 764 psychia-
trists treating 65,256 patients. Psychiatrists prescribed several ingredients (mean: 
9); however, prescribing behavior was relatively concentrated (mean HHI: 2,603; 
share of most preferred ingredient: 37.8%), with wide variation across psychiatrists 
(range HHI: 1,088-7,270; share of most preferred ingredient: 16.4%-84.7%; number 
of ingredients: 2-17). Having a higher share of SSI-eligible patients, patients with 
serious mental illnesses, non-Hispanic whites, and older patients was associated 
with less concentrated prescribing although effects were relatively small (all p< .05). 
Female psychiatrists had more concentrated prescribing than that of their male 
counterparts (p< .10). Psychiatrists affiliated with behavioral health organizations 
had more diversified antipsychotic prescribing. CONCLUSIONS: Antipsychotic pre-
scribing behavior in a large state Medicaid program was relatively concentrated 
and varied substantially across psychiatrists. Some psychiatrists treating Medicaid 
enrollees with antipsychotics may be limited in their ability to tailor treatment to 
individual patient needs and preferences.
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OBJECTIVES: Kentucky House Bill 1 (HB1) was enacted in July 2012 to address pre-
scription drug abuse and diversion. This legislation included stronger pain clinic 
regulations, mandatory prescriber registration with Kentucky’s prescription drug 
monitoring program (PDMP) and mandatory use of PDMP data prior to issuing a 
new controlled substance prescription. The purpose of this study was to assess 
the impact of HB1 on the concurrent prescribing of three controlled substances: 
an opioid (hydrocodone or oxycodone), alprazolam, and carisoprodol (OAC). This 
combination has been identified as a signal for misuse and diversion. METHODS: 
De-identified PDMP data from July 2009 through June 2013 was analyzed to deter-
mine the number of patients who concurrently received prescriptions for OAC. 
Concurrent was defined as receiving prescriptions for each OAC component within 
30 days. 12-month OAC totals were compared for each fiscal year (defined in KY as 
July 1 – June 30). Fiscal years were chosen for analysis based on the date of imple-
mentation of legislation (July 2012). Differences in mean number of patients receiv-
ing concurrent OAC prescriptions were analyzed using two-tailed t-tests for fiscal 
years pre and post legislation. RESULTS: The number of patients receiving concur-
rent OAC prescriptions for OAC during the study period were 22,423 (FY2010), 25,465 
(FY2011), 22,795 (FY2012), and 15,983 (FY2013). The number of patients receiving 
concurrent OAC prescriptions was significantly lower (P< 0.001) in FY2013 relative 
to FY2012. CONCLUSIONS: Implementation of Kentucky House Bill 1 was associ-
ated with a 29.9% decrease in the concurrent prescribing of a combination of CS 
commonly associated with misuse and diversion. Further studies to differentiate 
the relative impact of pain clinic regulations from the impact of mandatory regis-
tration and use legislation are warranted to determine the effectiveness of these 
approaches in curbing the abuse and diversion of prescription drugs.
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than low volume prescribers. Primary care providers were substantially less likely 
than psychiatrists to prescribe clozapine (OR = 0.55, p< 0.01) but just as likely to 
antipsychotic polypharmacy. CONCLUSIONS: Antipsychotic polypharmacy is used 
as much as clozapine in the care of Medicaid beneficiaries with schizophrenia, but 
many prescribers only use the former. Clinical and policy initiatives are needed to 
improve providers’ knowledge of clozapine and increase its use while decreasing 
use of antipsychotic polypharmacy.
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OBJECTIVES: To examine prevalence rates and co-relates of non-medical use of 
prescription stimulants for attention-deficit-hyperactivity disorder (ADHD) in a uni-
versity student population with respect to student demographics and academic 
characteristics. METHODS: A cross-sectional research design, utilizing a conveni-
ence sampling and self-administered paper and pencil questionnaire technique, 
was adopted. The survey consisted of a screening tool to measure symptoms of 
Adult ADHD Self-Report Scale (ASRS-v1.1) in conjunction with items to measure the 
extent of self-reported prescription drug abuse among students. The use of prescrip-
tion stimulants was profiled for students representing different schools and aca-
demic programs and reasons for the nonmedical use were documented. RESULTS: A 
sample of 638 completed surveys (response rate= 98.15%) was obtained with data on 
unauthorized use of prescription drugs. About 8.62% (N= 55) of the sample reported 
a current and past use of drugs such as Adderall, Ritalin, Dexedrine, Concerta, Cylert 
at least once. Of these, 76.9% used the drugs non-medically for enhancing academic 
performance and 23.1% used them for increasing alertness. The illicit drug usage 
was higher in the age group 18-23 years (87.2%) and was greater for males (64.1%). 
Overall, students from pharmacy school reported highest abuse (46.2%), followed 
by law school (20.5%), school of professional studies (12.8%) and business school 
(10.3%). Generally, undergraduate students reported greater use of prescription 
stimulants (69.2%) compared to graduate students (30.8%). A majority (66.7%) of 
the students were also attending professional degree programs. CONCLUSIONS: 
The current campus estimates are mostly in line with the national statistics (4.1% 
to 10.8%, according to the Center for Lawful Access and Abuse Deterrence, CLAAD, 
2013). Misuse and abuse of prescription stimulants among students is a growing 
problem and largely remains unaddressed. Development of campus educational 
tools to prevent sharing of prescription drugs and guidelines to recognize early 
warning signs to curb abuse are necessary.
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OBJECTIVES: Doctor shopping is a principle method of obtaining controlled sub-
stances (CS) for misuse and is an indicator of escalating drug abuse and fatal over-
dose. Currently, numerical thresholds are used to identify doctor shoppers, but 
a lack of consensus on criteria has led to wide variations in estimated rates. The 
goal of this study was to investigate the feasibility of using social network analy-
sis (SNA) to improve the specification and predictive validity of doctor shopping 
indicators. METHODS: i3 Innovus InVision™ data for the year 2009 was used to 
identify doctor shoppers using the 4 CS (opioid or benzodiazepine) prescriptions 
+ 4 pharmacies criterion. A network of physicians was created using indirect ties 
defined by co-prescription to the same doctor shopping patient. A visualization of 
the clinician network was created to assess clustering, and bivariate analyses were 
conducted to assess the relationship between physician centrality, or number of ties 
to other prescribers through a common doctor shopping patient, in the co-prescrib-
ing network and average characteristics of a physician’s patients. RESULTS: A total 
of 89,297 clinicians prescribed an opioid or benzodiazepine to at least one doctor 
shopper. The mean degree of centrality was 23.15 (SD 61.48 and ranged from 0-995). 
Physician degree centrality is positively correlated with patients’ average number 
of pharmacies (r= .28, p< .001), number of prescriptions (r= 0.21, p< .001), number of 
MPEs (r= 0.43; p< .001), and number of repeated visits to the same prescriber (r= 0.13, 
p< .001). The network visualization map revealed a large network of 7,288 doctors 
tied by 45,181 co-prescribing relationships. CONCLUSIONS: The results of this study 
confirm the feasibility of using SNA to identify doctor shoppers. Further studies 
using two-mode SNA are warranted to improve the specification and predictive 
validity of doctor shopping indicators and to determine the patient, clinician, and 
point-of-service characteristics associated with doctor shopping behavior.
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OBJECTIVES: To estimate prevalence of Adult ADHD (AADHD) symptoms among uni-
versity-based students across multiple academic disciplines. METHODS: A cross-
sectional research design, utilizing convenience sampling and self-administered 
paper and pencil questionnaire technique, was adopted. Adult students (> 18 years) 
were recruited from a university campus in New York City area. AADHD Self-Report 
Scale- v1.1 (ASRS v1.1), a pre-validated screening instrument, was used to assess 
performance along inattention, hyperactivity/impulsivity and combined symptom 
sets of adult ADHD. A score of 17 or more on an ASRS v1.1 scale between 0 and 72 
indicates the likelihood of ADHD, whereas a score of 24 or more indicates immense 
likelihood of ADHD. Individual component scores of ASRS were compared for stu-
dents from six different schools and programs within the university. RESULTS: 
The final sample consisted of 638 students from six different schools represent-
